The ASAM Alcohol Withdrawal Management Webinar Series - Pharmacotherapy
Includes a Live Event on 10/20/2020 at 12:00 PM (EDT)
- Non-Member - Free!
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
The ASAM Alcohol Withdrawal Management Webinar Series – Pharmacotherapy
The webinar follows the ASAM Alcohol Withdrawal Management Fundamentals webinar, which intends to aid clinicians in their clinical decision making and management of patients experiencing alcohol withdrawal syndrome, as written in The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.
Appropriate pharmacotherapy for alcohol withdrawal is a balance of alleviating symptoms and normalizing signs of AWS while preventing the adverse effects associated with the medications being administered. This webinar will provide an overview of the recommendations around the appropriate use of pharmacotherapy for patients with AWS.
Date: Tuesday, October 20, 2020
Time: 12:00 pm ET / 11:00 am CT/ 9:00 am PT
Speaker(s): Michael F. Weaver, MD, FASAM
By completing this session, you will be able to:
- 1. Summarize the guideline’s treatment recommendations around pharmacotherapy and discuss how they should be used in practice.
- 2. Recognize all medications that can be used to treat patients with AWS and explain the circumstances in which one form of medication is more effective than another.
- 3. Understand the limitations and risks associated with the various medications used to treat patients with AWS.
Michael Weaver, MD, DFASAM is a Professor in the Department of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addictions (CNRA) at the McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth). He received his M.D. degree from Northeast Ohio Medical University, and completed Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University (VCU) Health System, and he is Board-certified in Internal Medicine through the American Board of Internal Medicine and certified in Addiction Medicine through the American Board of Preventive Medicine. Dr. Weaver is the Sub-Board Chair for Addiction Medicine on the American Board of Preventive Medicine, and also serves as the Chair of the Examination Committee for certification in Addiction Medicine. He has been a member of ASAM for over 20 years and currently serves as a member of the Publications Council and the Annual Conference Program Planning Committee. He is currently involved in patient care, medical education, and research. Dr. Weaver sees patients in the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston. He has extensive experience teaching about addiction to medical students, residents, and community professionals at all levels. He has been involved in multiple research projects, and currently is collaborating with other researchers in the CNRA on studies involving cocaine, methamphetamine, marijuana, and electronic cigarettes. Dr. Weaver has multiple publications in the field of addiction medicine, including the book "Addiction Treatment" published by Carlat Publishing in 2017.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification (MOC)
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.
ABA Maintenance of Certification (MOC)
This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.
ABP Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABAM Transitional Maintenance of Certification (Tmoc)
Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.
American Board of Psychiatry and Neurology (ABPN)
Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.
Program Planning Committee, CME Committee, Medical Education Council (MEC)
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee Reviewer
Ed Salsitz, MD, DFASAM - No Financial Disclosures
Faculty & Planning Committee Disclosures
Lewis S. Nelson, MD, FASAM (Chair) – No Relevant Financial Disclosures
Kurt Kleinschmidt, MD, FASAM – No Relevant Financial Disclosures
Gerald E. Marti, MD, PhD – No Relevant Financial Disclosures
Darius Rastegar, MD, FASAM – No Relevant Financial Disclosures
Dazhe Cao, MD – No Relevant Financial Disclosures
George Kolodner, MD, DLFAPA, FASAM – Does Disclose: Kolmac Outpatient Recovery Centers, Self, Employment, Ownership Interest (includes stock, stock options, patent or other intellectual property) Clinical Condition: Substance Use Disorder
Michael F. Weaver, MD, DFASAM – No Relevant Financial Disclosures